495 related articles for article (PubMed ID: 29563103)
21. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy.
Walton ZE; Frigault MJ; Maus MV
Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525
[TBL] [Abstract][Full Text] [Related]
22. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
Siegler EL; Kenderian SS
Front Immunol; 2020; 11():1973. PubMed ID: 32983132
[TBL] [Abstract][Full Text] [Related]
23. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
24. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites.
Titov A; Petukhov A; Staliarova A; Motorin D; Bulatov E; Shuvalov O; Soond SM; Piacentini M; Melino G; Zaritskey A; Barlev NA
Cell Death Dis; 2018 Sep; 9(9):897. PubMed ID: 30181581
[TBL] [Abstract][Full Text] [Related]
25. Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy.
Chou CK; Turtle CJ
Bone Marrow Transplant; 2019 Aug; 54(Suppl 2):780-784. PubMed ID: 31431714
[TBL] [Abstract][Full Text] [Related]
26. Toxicities following CAR-T therapy for hematological malignancies.
Hernani R; Benzaquén A; Solano C
Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
[TBL] [Abstract][Full Text] [Related]
27. Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies.
Gust J; Taraseviciute A; Turtle CJ
CNS Drugs; 2018 Dec; 32(12):1091-1101. PubMed ID: 30387077
[TBL] [Abstract][Full Text] [Related]
28. [Practical aspects of the application of CAR T cells and management of their toxicities].
Bücklein V; Blumenberg V; Subklewe M
Dtsch Med Wochenschr; 2021 Sep; 146(17):1129-1137. PubMed ID: 34448189
[TBL] [Abstract][Full Text] [Related]
29. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Ruff MW; Siegler EL; Kenderian SS
Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
[TBL] [Abstract][Full Text] [Related]
30. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
Karschnia P; Jordan JT; Forst DA; Arrillaga-Romany IC; Batchelor TT; Baehring JM; Clement NF; Gonzalez Castro LN; Herlopian A; Maus MV; Schwaiblmair MH; Soumerai JD; Takvorian RW; Hochberg EP; Barnes JA; Abramson JS; Frigault MJ; Dietrich J
Blood; 2019 May; 133(20):2212-2221. PubMed ID: 30808634
[TBL] [Abstract][Full Text] [Related]
31. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
32. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity.
Jess J; Yates B; Dulau-Florea A; Parker K; Inglefield J; Lichtenstein D; Schischlik F; Ongkeko M; Wang Y; Shahani S; Cullinane A; Smith H; Kane E; Little L; Chen D; Fry TJ; Shalabi H; Wang HW; Satpathy A; Lozier J; Shah NN
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295816
[TBL] [Abstract][Full Text] [Related]
33. Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy.
Catalá E; Iacoboni G; Vidal-Jordana Á; Oristrell G; Carpio C; Vilaseca A; Cabirta A; Bosch F; Tintoré M; Barba P
Hematol Oncol; 2022 Aug; 40(3):482-487. PubMed ID: 35139240
[TBL] [Abstract][Full Text] [Related]
34. Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.
Panjwani MK; Smith JB; Schutsky K; Gnanandarajah J; O'Connor CM; Powell DJ; Mason NJ
Mol Ther; 2016 Sep; 24(9):1602-14. PubMed ID: 27401141
[TBL] [Abstract][Full Text] [Related]
35. CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions.
Hunter BD; Jacobson CA
J Natl Cancer Inst; 2019 Jul; 111(7):646-654. PubMed ID: 30753567
[TBL] [Abstract][Full Text] [Related]
36. Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.
Shalabi H; Wolters PL; Martin S; Toledo-Tamula MA; Roderick MC; Struemph K; Kane E; Yates B; Delbrook C; Mackall CL; Lee DW; Fry TJ; Shah NN
J Immunother; 2018 Sep; 41(7):350-358. PubMed ID: 30048343
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy
Chen Y; Li R; Shang S; Yang X; Li L; Wang W; Wang Y
Front Immunol; 2021; 12():623610. PubMed ID: 34093519
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
40. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.
Brammer JE; Braunstein Z; Katapadi A; Porter K; Biersmith M; Guha A; Vasu S; Yildiz VO; Smith SA; Buck B; Haddad D; Gumina R; William BM; Penza S; Saad A; Denlinger N; Vallakati A; Baliga R; Benza R; Binkley P; Wei L; Mocarski M; Devine SM; Jaglowski S; Addison D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34429331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
